X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
index medicus (9) 9
female (7) 7
male (7) 7
middle aged (7) 7
oncology (7) 7
aged (6) 6
chemotherapy (5) 5
disease-free survival (5) 5
cancer therapies (4) 4
colorectal cancer (4) 4
hematology, oncology and palliative medicine (4) 4
metastasis (4) 4
treatment outcome (4) 4
tumors (4) 4
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (3) 3
adenocarcinoma - drug therapy (3) 3
adult (3) 3
cancer (3) 3
clinical trials (3) 3
colorectal neoplasms - drug therapy (3) 3
colorectal neoplasms - pathology (3) 3
esophageal cancer (3) 3
life sciences (3) 3
medical prognosis (3) 3
patients (3) 3
retrospective studies (3) 3
santé publique et épidémiologie (3) 3
survival rate (3) 3
5-fluorouracil (2) 2
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (2) 2
acquired immune deficiency syndrome--aids (2) 2
adenocarcinoma - secondary (2) 2
aged, 80 and over (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
carcinoma (2) 2
care and treatment (2) 2
clinical study (2) 2
colorectal neoplasms - mortality (2) 2
disease control (2) 2
drug resistance (2) 2
drug therapy (2) 2
esophageal neoplasms - drug therapy (2) 2
esophageal neoplasms - pathology (2) 2
expression (2) 2
fluorouracil (2) 2
fluorouracil - administration & dosage (2) 2
folinic acid (2) 2
france (2) 2
heart attacks (2) 2
hematology (2) 2
histoplasmosis (2) 2
hiv (2) 2
hiv infections - complications (2) 2
human immunodeficiency virus--hiv (2) 2
incidence (2) 2
infections (2) 2
infectious diseases (2) 2
leucovorin (2) 2
medical colleges (2) 2
mutation (2) 2
oxaliplatin (2) 2
phenylurea compounds - therapeutic use (2) 2
predictive value of tests (2) 2
prognosis (2) 2
proteins (2) 2
pyridines - therapeutic use (2) 2
pyrimidines - administration & dosage (2) 2
pyrimidines - adverse effects (2) 2
studies (2) 2
survival (2) 2
1st-line treatment (1) 1
abridged index medicus (1) 1
acquired-resistance (1) 1
acute coronary syndromes (1) 1
adenocarcinoma - blood (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - pathology (1) 1
advanced colorectal cancer (1) 1
aids-related opportunistic infections - diagnosis (1) 1
aids-related opportunistic infections - drug therapy (1) 1
aids-related opportunistic infections - epidemiology (1) 1
aids-related opportunistic infections - microbiology (1) 1
albumin (1) 1
amphotericin b (1) 1
analysis (1) 1
angiogenesis inhibitors (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal, humanized (1) 1
antifungal agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antiparasitic agents (1) 1
antiretroviral agents (1) 1
antiretroviral drugs (1) 1
antiviral agents (1) 1
area under curve (1) 1
arrest (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 305 - 314
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 395 - 405
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 632 - 641
Journal Article
The Lancet Infectious Diseases, ISSN 1473-3099, 11/2017, Volume 17, Issue 11, pp. e334 - e343
Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with (pneumocystosis),... 
PENICILLIUM-MARNEFFEI INFECTION | CLINICAL-PRACTICE GUIDELINES | INSTITUTES-OF-HEALTH | INFECTIOUS DISEASES | POLYMERASE-CHAIN-REACTION | RECONSTITUTION INFLAMMATORY SYNDROME | HIV MEDICINE ASSOCIATION | NATURAL ANIMAL HOST | PNEUMOCYSTIS-CARINII PNEUMONIA | CRYPTOCOCCAL MENINGITIS | CHI MINH CITY | Mycoses - epidemiology | Fungi - classification | Humans | AIDS-Related Opportunistic Infections - drug therapy | Fungi - isolation & purification | Mycoses - microbiology | AIDS-Related Opportunistic Infections - diagnosis | AIDS-Related Opportunistic Infections - microbiology | Antifungal Agents - therapeutic use | Incidence | HIV Infections - immunology | Point-of-Care Systems | AIDS-Related Opportunistic Infections - epidemiology | Diagnostic Tests, Routine - methods | HIV Infections - complications | Mycoses - drug therapy | Mycoses - diagnosis | HIV testing | Mycoses | HIV patients | Health aspects | HIV infection | Antiviral agents | Medical colleges | Pneumonia | Bacterial pneumonia | HIV (Viruses) | Highly active antiretroviral therapy | Amphotericin B | Flucytosine | Antiparasitic agents | Drugs | Antiretroviral drugs | Histoplasmosis | Fungicides | Penicillium | Cryptococcosis | Infections | Drug resistance | Epidemiology | Disease control | Patients | CD4 antigen | Fungi | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Fungal diseases | Pneumocystosis | Human immunodeficiency virus--HIV | Cryptococcus | Diagnostic systems | Life Sciences | Santé publique et épidémiologie
Journal Article
Journal Article
Oncology, ISSN 0030-2414, 02/2016, Volume 90, Issue 2, pp. 88 - 96
Journal Article
Oncology, ISSN 0030-2414, 04/2008, Volume 73, Issue 3-4, pp. 185 - 191
Journal Article
European Journal of Cancer, ISSN 0959-8049, 1995, Volume 31, Issue 12, pp. 1945 - 1954
'Tomudex' (ZD1694), a direct and specific thymidylate synthase (TS) inhibitor entered phase III studies in November 1993. We present here the first analysis of... 
Phase III study | colorectal cancer | palliation | advanced colorectal cancer | thymidylate synthase inhibitor | Tomudex | chemotherapy | QUALITY | METHOTREXATE | BIOCHEMICAL MODULATION | FOLINIC ACID | FLUOROURACIL | ONCOLOGY | HIGH-DOSE LEUCOVORIN | CARCINOMA | LIFE
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.